文献速递神经肿瘤

颅内胶质瘤治疗成本与生存的价值驱动结局数据库回顾性队列分析

Evaluation of cost and survival in intracranial gliomas using the Value Driven Outcomes database: a retrospective cohort analysis.
PubMed 文献 · J Neurosurg · 2019-03-29

该回顾性队列研究利用Value Driven Outcomes数据库分析263例颅内胶质瘤手术患者的成本驱动因素与生存关系。设施成本占总成本64.4%为主要驱动因素,多因素分析仅住院时间与总成本显著相关;WHO III和IV级肿瘤更广泛切除与生存改善显著相关。

要点

  • 设施成本占总成本64.4%,是颅内胶质瘤手术治疗的主要成本驱动因素。
  • 多因素分析中仅住院时间与总成本显著相关(p=0.0001)。
  • WHO III级和IV级肿瘤更广泛切除与生存显著改善相关(p=0.004和p=0.02)。

核心结论

  • 理解医疗成本具有挑战性,因为医疗服务提供高度复杂、碎片化和多变。
  • 采用降低设施成本和限制住院时间的有效策略可能是降低颅内胶质瘤治疗成本最重要的方面。

研究设计与样本

  • 回顾性队列研究,使用作者所在机构2011年8月至2018年2月治疗的颅内胶质瘤患者的病历和Value Driven Outcomes(VDO)数据库。
  • 共263例符合纳入标准的颅内胶质瘤患者纳入分析(WHO I级2.0%;II级18.5%;III级18.1%;IV级61.4%)。

主要发现

  • 设施成本是主要成本驱动因素(64.4%),其次为耗材(16.2%)、药房(10.1%)、影像(4.5%)和实验室(4.7%)。
  • 单因素分析显示美国麻醉医师协会体质状态(p=0.002)、肿瘤复发(p=0.06)、卡氏功能状态评分(p=0.002)、住院时间(p=0.0001)和最大肿瘤尺寸(p=0.03)对总成本有显著贡献。
  • 多因素分析中仅住院时间(p=0.0001)对总成本有显著贡献。
  • WHO III级和IV级肿瘤更广泛切除与生存显著改善相关(分别为p=0.004和p=0.02)。

临床怎么用

  • 采用有效策略降低设施成本并限制住院时间,可能是降低颅内胶质瘤治疗成本最重要的方面。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gliomas occur in 3-4 individuals per 100,000 individuals and are one of the most common primary brain tumors. Treatment options are limited for gliomas despite the progressive nature of the disease. The authors used the Value Driven Outcomes (VDO) database to identify cost drivers and subgroups that are involved in the surgical treatment of gliomas. METHODS: A retrospective cohort of patients with gliomas treated at the authors' institution from August 2011 to February 2018 was evaluated using medical records and the VDO database. RESULTS: A total of 263 patients with intracranial gliomas met the authors' inclusion criteria and were included in the analysis (WHO grade I: 2.0%; grade II: 18.5%; grade III: 18.1%; and grade IV: 61.4%). Facility costs were the major (64.4%) cost driver followed by supplies (16.2%), pharmacy (10.1%), imaging (4.5%), and laboratory (4.7%). Univariate analysis of cost contributors demonstrated that American Society of Anesthesiologists physical status (p = 0.002), tumor recurrence (p = 0.06), Karnofsky Performance Scale score (p = 0.002), length of stay (LOS) (p = 0.0001), and maximal tumor size (p = 0.03) contributed significantly to the total costs. However, on multivariate analysis, only LOS (p = 0.0001) contributed significantly to total costs. More extensive tumor resection in WHO grade III and IV tumors was associated with significant improvement in survival (p = 0.004 and p = 0.02, respectively). CONCLUSIONS: Understanding care costs is challenging because of the highly complex, fragmented, and variable nature of healthcare delivery. Adopting effective strategies that would reduce facility costs and limit LOS is likely the most important aspect in reducing intracranial glioma treatment costs.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wilde H, Azab MA, Abunimer AM, et al. Evaluation of cost and survival in intracranial gliomas using the Value Driven Outcomes database: a retrospective cohort analysis. J Neurosurg. 2019. PMID: 30925470. doi:10.3171/2018.12.JNS183109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。